WAVE Life Sciences Shares Outstanding 2014-2021 | WVE

WAVE Life Sciences shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
WAVE Life Sciences Annual Shares Outstanding
(Millions of Shares)
2020 39
2019 34
2018 29
2017 27
2016 23
2015 11
2014 4
2013 2
WAVE Life Sciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 50
2021-03-31 49
2020-12-31 39
2020-09-30 38
2020-06-30 35
2020-03-31 34
2019-12-31 34
2019-09-30 34
2019-06-30 34
2019-03-31 33
2018-12-31 29
2018-09-30 29
2018-06-30 29
2018-03-31 28
2017-12-31 27
2017-09-30 28
2017-06-30 27
2017-03-31 24
2016-12-31 23
2016-09-30 23
2016-06-30 23
2016-03-31 22
2015-12-31 11
2015-09-30 9
2015-06-30 9
2015-03-31 8
2014-12-31
2014-09-30 4
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.313B $0.020B
WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29